-
FDA IDE validation of multiple myeloma MRD test by flow cytometry Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-18 Dragan Jevremovic, Min Shi, Pedro Horna, Gregory E. Otteson, Michael M. Timm, Shannon A. Bennett, Linda B. Baughn, Patricia T. Greipp, Wilson I. Gonsalves, Prashant Kapoor, Morie A. Gertz, Moritz Binder, Francis K. Buadi, Angela Dispenzieri, Taxiarchis Kourelis, Eli Muchtar, Jiehao Zhou, S. Vincent Rajkumar, Shaji K. Kumar, Horatiu Olteanu
Two recent decisions by the Food and Drug Administration will likely significantly impact testing for multiple myeloma (MM) minimal residual disease (MRD). First, on April 12, 2024, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted to approve the use of MRD as an end point for accelerated approval of new treatments for patients with MM.1 This was a result of near 10 years effort by multiple
-
The importance of autologous stem cell transplantation in improving outcomes in newly diagnosed patients with multiple myeloma Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-18 Morie A. Gertz
CONFLICT OF INTEREST STATEMENT The author declares no conflict of interest.
-
Clearance of pathogenic erythrocytes is maintained despite spleen dysfunction in children with sickle cell disease Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-17 Abdoulaye Sissoko, Astan Cissé, Clémence Duverdier, Mickaël Marin, Lucie Dumas, Sandra Manceau, Blandine Maître, Anita Eckly, Aurélie Fricot‐Monsinjon, Camille Roussel, Papa Alioune Ndour, Michael Dussiot, Safi Dokmak, Béatrice Aussilhou, Jeanne Dembinski, Alain Sauvanet, François Paye, Mickaël Lesurtel, Jérôme Cros, Dominique Wendum, Magali Tichit, David Hardy, Carmen Capito, Slimane Allali, Pierre
In children with sickle cell disease (SCD), splenectomy is immediately beneficial for acute sequestration crises and hypersplenism (ASSC/HyS) but portends a long‐term risk of asplenia‐related complications. We retrieved peripheral and splenic red blood cells (RBCs) from 17 SCD children/teenagers undergoing partial splenectomy for ASSC/HyS, 12 adult subjects without RBC‐related disease undergoing splenectomy
-
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-17 Maël Heiblig, Clément Gourguechon, Philippe Guilpain, Cristina Bulai‐Livideanu, Stéphane Barete, Yannick Chantran, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Jérémie Lespinasse, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Catharina Chatain, Ghandi Damaj, Thomas Ballul, Celine Greco, Laura Polivka, Laurent Frenzel, Cécile Meni, Hassiba Bouktit, Dina Benabou
-
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-16 Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J. Walker, James S. Blachly, Jessica Kohlschmidt, Shelley Orwick, Andrew J. Carroll, Richard A. Larson, Jonathan E. Kolitz, Bayard L. Powell, Richard M. Stone, John C. Byrd, Ann-Kathrin Eisfeld, Alice S. Mims
Acute myeloid leukemia (AML) is a biologically and clinically heterogenous disease with diverse genetic abnormalities1-6 and a wide-ranging white blood cell counts (WBC) at diagnosis.1 The 2022 European LeukemiaNet (ELN) genetic-risk classification incorporates cytogenetic and selected molecular alterations to define Favorable, Intermediate, and Adverse genetic-risk groups providing valuable prognostic
-
The cognitive age in medicine: Artificial intelligence, large language models, and iterative intelligence Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-16 John Nosta
CONFLICT OF INTEREST STATEMENT The author declares no conflicts of interest.
-
Thrombotic thrombocytopenic purpura masquerading as Evans syndrome Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-16 Sarah E. Mudra, Kaleb Ardoin, Vanya Aggarwal, Garrett Diltz, Pedro E. Alcedo Andrade, Catherine M. Broome
1 CASE PRESENTATION A 26-year-old female with a history of chronic urticaria (treated with omalizumab in the past) and recently treated chlamydia trachomatis infection presented to an outside emergency department after a syncopal episode. She endorsed a three-day history of nausea, vomiting, fatigue, and ecchymoses. Initial laboratory analysis revealed macrocytic anemia (hemoglobin 4.6 g/dL) with a
-
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials Leukemia (IF 12.8) Pub Date : 2024-09-16 Mouhamad Khouja, Linmiao Jiang, Karol Pal, Peter James Stewart, Binaya Regmi, Martin Schwarz, Wolfram Klapper, Stefan K. Alig, Nikos Darzentas, Hanneke C. Kluin-Nelemans, Olivier Hermine, Martin Dreyling, David Gonzalez de Castro, Eva Hoster, Christiane Pott
-
Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma Leukemia (IF 12.8) Pub Date : 2024-09-16 Brandon S. Willis, Kevin Mongeon, Hannah Dry, India L. Neveras, Nadezda Bryan, Meghana Pandya, Justine Roderick-Richardson, Wendan Xu, Li Yang, Alan Rosen, Corinne Reimer, Liliana Tuskova, Pavel Klener, Jerome T. Mettetal, Georg Lenz, Simon T. Barry
-
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-16 David Sedloev, Qian Chen, Julia M. Unglaub, Nicola Schanda, Yao Hao, Eleni Besiridou, Brigitte Neuber, Anita Schmitt, Simon Raffel, Yi Liu, Maike Janssen, Carsten Müller-Tidow, Michael Schmitt, Tim Sauer
Relapsed and refractory acute myeloid leukemia (AML) carries a dismal prognosis. CAR T cells have shown limited efficacy in AML, partially due to dysfunctional autologous T cells and the extended time for generation of patient specific CAR T cells. Allogeneic NK cell therapy is a promising alternative, but strategies to enhance efficacy and persistence may be necessary. Proteasome inhibitors (PI) induce
-
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-09-16 Bon-Kwan Koo, Eun-Ji Choi, Ju Hyun Moon, Ji Yun Kim, Hyunkyung Park, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo-Hyung Lee, Eun Kyung Choi, Eunji Kim, Je-Hwan Lee, Eun-Hye Hur
-
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-09-16 Yu Liu, Wenbing Liu, Anli Lai, Yihan Mei, Ying Wang, Hui Wei, Qing Rao, Runxia Gu, Yingchang Mi, Min Wang, Jianxiang Wang, Shaowei Qiu
-
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy Blood Cancer J. (IF 12.9) Pub Date : 2024-09-16 Sophia Gross, Jana Ihlow, Leonie Busack, Kacper Adamiak, Jens Schrezenmeier, Julia Jesse, Michaela Schwarz, Anne Flörcken, Lam Giang Vuong, Kathrin Rieger, Jan Krönke, Philipp le Coutre, Vivien Boldt, Ann-Christin von Brünneck, David Horst, Thomas Burmeister, Igor-Wolfgang Blau, Ulrich Keller, Lars Bullinger, Jörg Westermann
-
HDAC7 is a potential therapeutic target in acute erythroid leukemia Leukemia (IF 12.8) Pub Date : 2024-09-15 Wenyu Zhang, Keita Yamamoto, Yu-Hsuan Chang, Tomohiro Yabushita, Yangying Hao, Ruka Shimura, Jakushin Nakahara, Shiori Shikata, Kohei Iida, Qianyi Chen, Xichen Zhang, Toshio Kitamura, Susumu Goyama
-
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-13 Di Liu, Leilei Wu, Xiaoling Xu, Shuangyan Yang, Ming Liu, Min Hu, Shengxiang Ren, Yaping Xu
Combination of immunotherapy with radiotherapy is under active investigation. The PACIFIC trial firmly established the treatment paradigm of consolidation immunotherapy following definitive chemoradiotherapy, inspiring a series of similar or exploratory combination regimens. This summary highlighted six reports updated in the 2024 ASCO Annual Meeting.
-
c-Myc alone is enough to reprogram fibroblasts into functional macrophages J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-12 Shanshan Li, Guoyu Chen, Xia Huang, Yingwen Zhang, Shuhong Shen, Haizhong Feng, Yanxin Li
Macrophage-based cell therapy is promising in solid tumors, but the efficient acquisition of macrophages remains a challenge. Induced pluripotent stem cell (iPSC)-induced macrophages are a valuable source, but time-consuming and costly. The application of reprogramming technologies allows for the generation of macrophages from somatic cells, thereby facilitating the advancement of cell-based therapies
-
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients Blood Cancer J. (IF 12.9) Pub Date : 2024-09-13 Nisha S. Joseph, Jonathan L. Kaufman, Vilas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sara M. DiCamillo, Danielle Roberts, Ajay K. Nooka, Sagar Lonial
-
Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study Leukemia (IF 12.8) Pub Date : 2024-09-12 Florence Rabian, Sylvie Chevret, Bérengère Gruson, Sylvain Thépot, Anouk Walter-Petrich, Thorsten Braun, Norbert Vey, José Miguel Torregrosa-Diaz, Pierre Peterlin, Andrea Toma, Maud D’Aveni, Jacques Delaunay, Laurence Legros, Nathalie Droin, Fatiha Chermat, Daniel Lusina, Lionel Adès, Rosa Sapena, Eric Solary, Pierre Fenaux, Raphael Itzykson
-
USP4 regulates ribosome biogenesis and protein synthesis for hematopoietic stem cell regeneration and leukemia progression Leukemia (IF 12.8) Pub Date : 2024-09-12 Bo Liu, Xianli Zhang, Yuanyuan Zhou, Haiping Liu, Zhenkun Wang, Yuting Fu, Qiongdan Gao, Xiang Cheng, Qingyuan Sun, Zhenyu Ju
-
Bispecific antibodies in the treatment of multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2024-09-12 Anup Joseph Devasia, Ajai Chari, Guido Lancman
-
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2024-09-12 Carolien C. H. M. Maas, David van Klaveren, Müjde Durmaz, Otto Visser, Djamila E. Issa, Eduardus F. M. Posthuma, Josée M. Zijlstra, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed
-
-
Therapy response in AML: a tale of two T cells Blood (IF 21.0) Pub Date : 2024-09-12 Livius Penter, Catherine J. Wu
-
-
-
A menin-KMT2A inhibitor to overcome resistance Blood (IF 21.0) Pub Date : 2024-09-12 Caroline A. Heckman
-
Typhoidal cells: unraveling the diagnostic conundrum in brucellosis instead Blood (IF 21.0) Pub Date : 2024-09-12 Ruimin Li, Xiaoqiang Lian
-
Anti-CD37 CAR T cells: another arrow in the quiver Blood (IF 21.0) Pub Date : 2024-09-12 Dimitrios Mougiakakos
-
Cybersecurity and the blood supply: The vulnerabilities of the technological revolution Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-12 Jeremy W. Jacobs, Nicole De Simone, Miriam Andrea Duque, Yanyun Wu, Dawn C. Ward, Jennifer S. Woo, Laura D. Stephens, Elizabeth S. Allen, Mandy F. O'Leary, Sheharyar Raza, Garrett S. Booth, Brian D. Adkins
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion‐dependent β‐thalassemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-12 Daniele Lello Panzieri, Dario Consonni, Natalia Scaramellini, Guido Ausenda, Francesca Granata, Nancy Caponio, Lorena Duca, Simona Leoni, Silvia Elli, Marta Ferraresi, Vittorio Bolis, Cristina Curcio, Milena Agata Irrera, Diletta Maira, Giovanna Graziadei, Elena Cassinerio, Maria Domenica Cappellini, Rayan Bou‐Fakhredin, Valentina Brancaleoni, Irene Motta
Luspatercept is the first erythropoiesis-modulating agent approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treating anemia in adult transfusion-dependent β-thalassemia (TDT) patients. As observed in clinical trials1 and real-life experience,2 response to luspatercept in TDT is heterogeneous. It can range from patients who do not respond to those who become
-
CXCR4 as a therapeutic target in acute myeloid leukemia Leukemia (IF 12.8) Pub Date : 2024-09-11 Jan Korbecki, Mateusz Bosiacki, Patrycja Kupnicka, Katarzyna Barczak, Dariusz Chlubek, Irena Baranowska-Bosiacka
-
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study Leukemia (IF 12.8) Pub Date : 2024-09-11 Susan R. Rheingold, Deepa Bhojwani, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, John A. Kairalla, Mary Shago, Nyla A. Heerema, Andrew J. Carroll, Heather Breidenbach, Michael Borowitz, Brent L. Wood, Anne L. Angiolillo, Barbara L. Asselin, W. Paul Bowman, Patrick Brown, ZoAnn E. Dreyer, Kimberly P. Dunsmore, Joanne M. Hilden, Eric Larsen, Kelly Maloney, Yousif Matloub, Leonard A. Mattano, Stuart S. Winter
-
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia Leukemia (IF 12.8) Pub Date : 2024-09-11 Daniel Hägerstrand, Blaž Oder, Diego Cortese, Ying Qu, Amrei Binzer-Panchal, Cecilia Österholm, Teresa Del Peso Santos, Leily Rabbani, Hassan Foroughi Asl, Aron Skaftason, Viktor Ljungström, August Lundholm, Maria Koutroumani, Zahra Haider, Cecilia Jylhä, John Mollstedt, Larry Mansouri, Karla Plevova, Andreas Agathangelidis, Lydia Scarfò, Marine Armand, Alice F. Muggen, Neil E. Kay, Tait Shanafelt
-
Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-11 Yingling Zu, Huifang Zhao, Jianling Chen, Huibing Dang, Yanrong Shi, Lixin Liang, Shuhao Mei, Yongping Song, Yanli Zhang
Unintended pregnancy for female patients with chronic myeloid leukemia (CML) raises the discussion of treatment choices due to the teratogenicity of tyrosine kinase inhibitor (TKI). We report 51 accidental pregnant CML chronic phase (CP) patients with TKI withdrawal immediately after pregnancy from December 2010 to February 2024 to observe the effect of short exposure to TKI on the fetus and the infant
-
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial Blood Cancer J. (IF 12.9) Pub Date : 2024-09-11 Arleigh McCurdy, Donna Reece, Martha L. Louzada, Darrell White, Stephen Parkin, Michael P. Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Suzanne Trudel
-
Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2024-09-11 Marietheres Evers, Thorsten Stühmer, Martin Schreder, Torsten Steinbrunn, Martina Rudelius, Franziska Jundt, Regina Ebert, Tanja Nicole Hartmann, Ralf Christian Bargou, Andreas Rosenwald, Ellen Leich
-
Machine‐learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-11 Shankara K. Anand, Andrew Staron, Lisa M. Mendelson, Tracy Joshi, Natasha Burke, Vaishali Sanchorawala, Ashish Verma
Immunoglobulin light chain (AL) amyloidosis is a multisystem disease with varied treatment options and disease‐related outcomes. Current staging systems rely on a limited number of cardiac, renal, and plasma cell dyscrasia biomarkers. To improve prognostication for all‐cause mortality and end‐stage kidney disease (ESKD), we applied unsupervised machine learning using a comprehensive set of clinical
-
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation Leukemia (IF 12.8) Pub Date : 2024-09-10 Laura Rachele Bettini, Grazia Fazio, Claudia Saitta, Rocco Piazza, Sonia Palamini, Chiara Buracchi, Stefano Rebellato, Nicola Santoro, Cristiano Simone, Andrea Biondi, Giovanni Cazzaniga
-
Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia? Leukemia (IF 12.8) Pub Date : 2024-09-10 Janine Stutterheim, Rachella van der Waarden, Hester A. de Groot-Kruseman, Edwin Sonneveld, Valérie de Haas, Rana Dandis, C. Ellen van der Schoot, Vincent H. J. van der Velden, Rob Pieters
-
Global, regional, and national burden of Burkitt lymphoma from 1990 to 2021 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2021 Blood Cancer J. (IF 12.9) Pub Date : 2024-09-09 Ying Wang, Ziyuan Shen, Chenlu He, Xing Xing, Zaixiang Tan, Wei Sang
-
Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN. Blood (IF 21.0) Pub Date : 2024-09-10 Edimara Reis,Rebecca Buonpane,Hamza Celik,Caroline Marty,Angela Lei,Fatoumata Jobe,Mark Rupar,Yue Zhang,Darlise DiMatteo,Rahel Awdew,Bianca L Ferreira,Lynn Leffet,Lu Lu,Elodie Rosa,Maxime Evrard,Gaurang Trivedi,Brittney Wass,April Horsey,Xin He,Maryanne B Covington,Alla Volgina,Florence Pasquier,Laurence Legros,Guillemette Fouquet,William Vainchenker,Yan-Ou Yang,Breann Barker,Jing Zhou,Shaun Stewart
Mutations in calreticulin (mutCALR) are the second most common drivers of myeloproliferative neoplasms (MPNs) and yet, the current therapeutic landscape lacks a selective agent for mutCALR-expressing MPNs. Here we show that the monoclonal antibody INCA033989 selectively targets mutCALR-positive cells. INCA033989 antagonized mutCALR-driven signaling and proliferation in engineered cell lines and primary
-
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis. Blood (IF 21.0) Pub Date : 2024-09-10 Brooj Abro,Matthew J Maurer,Thomas M Habermann,Richard Burack,Jennifer R Chapman,Jonathon B Cohen,Jonathan W Friedberg,Giorgio Ga Inghirami,Brad S Kahl,Melissa C Larson,Brian L Link,Izidore S Lossos,Peter Martin,Timothy McDonnell,Loretta J Nastoupil,Shaun Riska,Sergei I Syrbu,Francisco Vega,Kiran Vij,Christopher R Flowers,James R Cerhan,David L Jaye,Andrew L Feldman
Recent introduction of two different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differences between the classifications will impact <1% of non-Hodgkin lymphomas.
-
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-10 Talha Badar, Ravi Narra, Alice S. Mims, Michael G. Heckman, Rory M. Shallis, Sheikh Fahad, Cameron Hunter, Vamsi Kota, Tamer Adel Othman, Brian Jonas, Shreya Desai, Guilherme Sacchi de Camargo Correia, Anand Patel, Adam S. DuVall, Neil Palmisiano, Emily Curran, Zulfa Omer, Anjali Advani, Ehab Atallah, Mark Litzow
-
Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-10 Rajshekhar Chakraborty, Hira Mian
To the Editor: With the advent of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (CD38mAbs), the outcomes of transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (MM) have substantially improved in the last decade.1-3 Currently, there are two widely accepted standard-of-care regimens in newly diagnosed TIE MM: daratumumab-lena
-
Early-life tobacco exposure is causally implicated in aberrant RAG-mediated recombination in childhood acute lymphoblastic leukemia Leukemia (IF 12.8) Pub Date : 2024-09-09 Tanxin Liu, Keren Xu, Anmol Pardeshi, Swe Swe Myint, Alice Y. Kang, Libby M. Morimoto, Michael R. Lieber, Joseph L. Wiemels, Scott C. Kogan, Catherine Metayer, Adam J. de Smith
-
Cohesin mutations in acute myeloid leukemia Leukemia (IF 12.8) Pub Date : 2024-09-09 Austin Boucher, Josiah Murray, Sridhar Rao
-
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol. (IF 15.4) Pub Date : 2024-09-09 Claire N Harrison,Ruben Mesa,Moshe Talpaz,Haifa Kathrin Al-Ali,Blanca Xicoy,Francesco Passamonti,Francesca Palandri,Giulia Benevolo,Alessandro Maria Vannucchi,Clemence Mediavilla,Alessandra Iurlo,InHo Kim,Shelonitda Rose,Patrick Brown,Christopher Hernandez,Jia Wang,Jean-Jacques Kiladjian
BACKGROUND Most patients with myelofibrosis develop ruxolitinib intolerance or disease that is relapsed or refractory, and survival rates after ruxolitinib discontinuation are poor. We aimed to evaluate the safety and efficacy of fedratinib versus best available therapy (BAT) in patients with myelofibrosis previously treated with ruxolitinib. METHODS FREEDOM2 was a multicentre, open-label, randomised
-
Haploidentical hematopoietic cell transplantation as a platform for natural killer cell immunotherapy Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-09 Rémy Duléry, Sara Piccinelli, Mohmad Shahnawaz Beg, Ji Eun Jang, Rizwan Romee
-
JAK2V617F impairs lymphoid differentiation in myeloproliferative neoplasms Leukemia (IF 12.8) Pub Date : 2024-09-07 Daniel C. Choi, Nassima Messali, Narasimha Rao Uda, Ghaith Abu-Zeinah, Pouneh Kermani, Maria Mia Yabut, Heidi E. L. Lischer, Franco Castillo Tokumori, Katie Erdos, Thomas Lehmann, Marta Sobas, Tata Nageswara Rao, Joseph M. Scandura
-
Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms Leukemia (IF 12.8) Pub Date : 2024-09-07 Sian Faustini, Y. L. Tracey Chan, Lilli Evans, Emily Collman, Alec Rapson, Claire Backhouse, Annabelle Emery, John P. Campbell, Sally Moore, Alex Richter, Guy Pratt, Mark T. Drayson, Jennifer L. J. Heaney
-
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old. Blood (IF 21.0) Pub Date : 2024-09-06 Roland B Walter,Victoria Potter,Charles Craddock
The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of allogeneic hematopoietic cell transplantation (allo-HCT) in adults age ≥70 with AML. However, while potentially curative, non-relapse mortality and relapse represent the main causes of treatment failure, highlighting the importance
-
Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-cell Lymphoma. Blood (IF 21.0) Pub Date : 2024-09-06 Katie Maurer,Isabella N Grabski,Roch Houot,Satyen H Gohil,Shogo Miura,Robert A Redd,Haoxiang Lyu,Wesley Lu,Yohei Arihara,Justin Budka,Mikaela McDonough,Michela Ansuinelli,Carol G Reynolds,Heather Jacene,Shuqiang Li,Kenneth J Livak,Jerome Ritz,Brodie Miles,Mike Mattie,Donna S Neuberg,Rafael A Irizarry,Philippe Armand,Catherine J Wu,Caron A Jacobson
Engineered cellular therapy with CD19-targeting chimeric antigen receptor T-cells (CAR-T) has revolutionized outcomes for patients with relapsed/refractory Large B-Cell Lymphoma (LBCL), but the cellular and molecular features associated with response remain largely unresolved. We analyzed serial peripheral blood samples ranging from day of apheresis (day -28/baseline) to 28 days after CAR-T infusion
-
Continued need for autologous transplantation in relapsed myeloma. Lancet Haematol. (IF 15.4) Pub Date : 2024-09-06 Elias K Mai
-
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. (IF 15.4) Pub Date : 2024-09-06 Gordon Cook,A John Ashcroft,Ethan Senior,Catherine Olivier,Anna Hockaday,Jeanine Richards,Jamie D Cavenagh,John A Snowden,Mark T Drayson,Ruth de Tute,Lesley Roberts,Roger G Owen,Kwee Yong,Mamta Garg,Kevin Boyd,Hamdi Sati,Sharon Gillson,Mark Cook,David A Cairns,Christopher Parrish,
BACKGROUND The efficacy of consolidation and maintenance in the context of salvage autologous haematopoietic stem-cell transplantation (HSCT) for relapsed multiple myeloma remains unclear. We aimed to assess whether consolidation after salvage autologous HSCT, using ixazomib, thalidomide, and dexamethasone, followed by maintenance with single agent ixazomib is superior to observation. METHODS This
-
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-06 Stephen M. Ansell
Disease OverviewHodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 8570 new patients annually and representing ~10% of all lymphomas in the United States.DiagnosisHL is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL (also called nodular lymphocyte predominant B‐cell lymphoma). Nodular sclerosis, mixed cellularity, lymphocyte depletion
-
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia Leukemia (IF 12.8) Pub Date : 2024-09-05 Jianxiang Wang, Bin Jiang, Jian Li, Ligen Liu, Xin Du, Hao Jiang, Jianda Hu, Menghe Yuan, Taishi Sakatani, Takeshi Kadokura, Masato Takeuchi, Masanori Kosako, Xiao Ma, Larisa Girshova, Jerome Tan, Sergey Bondarenko, Lily Wong Lee Lee, Archrob Khuhapinant, Elena Martynova, Nahla Hasabou
-
Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia Leukemia (IF 12.8) Pub Date : 2024-09-04 Cédric G. van der Ham, Lianne C. Suurenbroek, Michelle M. Kleisman, Željko Antić, Stefan H. Lelieveld, Marley Yeong, Liset Westera, Edwin Sonneveld, Peter M. Hoogerbrugge, Vincent H. J. van der Velden, Frank N. van Leeuwen, Roland P. Kuiper
-
Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-04 Wei-Fang Zuo, Qiwen Pang, Xinyu Zhu, Qian-Qian Yang, Qian Zhao, Gu He, Bo Han, Wei Huang
Heat shock proteins are essential molecular chaperones that play crucial roles in stabilizing protein structures, facilitating the repair or degradation of damaged proteins, and maintaining proteostasis and cellular functions. Extensive research has demonstrated that heat shock proteins are highly expressed in cancers and closely associated with tumorigenesis and progression. The "Hallmarks of Cancer"
-
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2024-09-05 Ricardo D. Parrondo, Betsy R. LaPlant, Jamie Elliott, Andre Fernandez, Caitlin J. Flott, Diedre Arrington, Dustin Chapin, Jade Brown, Saurav Das, Vivek Roy, Asher A. Chanan-Khan, Sikander Ailawadhi
-
Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms Blood Cancer J. (IF 12.9) Pub Date : 2024-09-05 Samantha A. Banks, Paul Decker, Eoin P. Flanagan, Anastasia Zekeridou, Ronald S. Go, Jithma P. Abeykoon, Gaurav Goyal, Jason R. Young, Matthew J. Koster, Robert Vassallo, Jay H. Ryu, Caroline J. Davidge-Pitts, Aishwarya Ravindran, Julio C. Sartori Valinotti, N. Nora Bennani, Mithun V. Shah, Karen L. Rech, Corrie R. Bach, Jeanette E. Eckel-Passow, W. Oliver Tobin